Regulations

Rare disease regulations play a critical role in ensuring patients have access to safe and effective treatments. From orphan drug policies to expedited approval pathways, understanding these frameworks can empower stakeholders to advocate for change. Here, we break down the complexities of regulations, their impact on patients, and the opportunities they create for advancing rare disease care.

FDA Approves Lembaz (Adrabetadex) for Niemann Pick Type C

FDA Approves Lembaz (Adrabetadex) for Niemann Pick Type C

The US Food and Drug Administration (FDA) has approved Lembaz (adrabetadex) for the treatment of infantile-Niemann Pick disease type C (NPC). NPC is a complex lysosomal storage disorder mainly characterized by the accumulation of unesterified cholesterol in lysosomes....

More

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

Ultragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare Brief

On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays....

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10

On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It's the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. ...

New Rare Disease Center of Excellence and FDA Advances in Rare Disease | The CheckRare Brief Ep 9

This week on The CheckRare Brief, we are joined by Eugene Lee, CMI Media Group’s Group President, Specialty Communications, for an industry perspective on some of the biggest developments in rare...

Recent Videos

Biomarkers and Beyond: Integrating AI in Rare Disease Management

Biomarkers and Beyond: Integrating AI in Rare Disease Management

Staci Kallish, DO, Clinical Geneticist at Penn Medicine in Philadelphia, is helping to lead a new wave of innovation at the intersection of artificial intelligence (AI) and rare disease care.